{
  "id": "6028fc001cb411341a000102",
  "type": "list",
  "question": "Which two antibodies directed towards the CGRP ligand, were approved by the FDA in September 2018.",
  "ideal_answer": "Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30550780"
  ],
  "snippets": [
    {
      "text": "Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30550780",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Fremanezumab, Galcanezumab"
}